Evaluation of Neutrophil Gelatinase-Associated Lipocalin as a Predictor of Glomerular Filtration Rate and Amikacin Clearance During Early Rat Endotoxemia: Comparison with Traditional Endogenous and Exogenous Biomarkers.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Springer France Country of Publication: France NLM ID: 7608491 Publication Model: Print Cited Medium: Internet ISSN: 2107-0180 (Electronic) Linking ISSN: 03787966 NLM ISO Abbreviation: Eur J Drug Metab Pharmacokinet Subsets: MEDLINE
    • Publication Information:
      Publication: <2010- >: Paris : Springer France
      Original Publication: Paris, Edifor.
    • Subject Terms:
    • Abstract:
      Background and Objectives: Renal elimination of amikacin and other aminoglycosides is slowed down in sepsis-induced acute kidney injury increasing the risk of adverse effects. Since neutrophil gelatinase-associated lipocalin (NGAL) and aminoglycosides share the mechanisms for renal excretion, the predictive power of NGAL was examined towards the changes in amikacin pharmacokinetics during early endotoxemia in anesthetized Wistar rats.
      Methods: Endogenous biomarkers of inflammation and acute kidney injury were assessed including NGAL in saline-injected controls and two groups of rats challenged with an intravenous injection of bacterial lipopolysaccharide (5 mg/kg)-a fluid-resuscitated group (LPS) and a fluid-resuscitated group infused intravenously with 8 μg/kg/h terlipressin (LPS-T). Sinistrin and amikacin were infused to measure glomerular filtration rate (GFR) and amikacin clearance (CL am ). The investigations included blood gas analysis, chemistry and hematology tests and assessment of urine output, creatinine clearance (CL cr ) and sinistrin clearance (CL sini ).
      Results: Within 3 h of injection, systemic and renal inflammatory responses were induced by lipopolysaccharide. Gene and protein expression of NGAL was increased in the kidneys and the concentrations of NGAL in the plasma (pNGAL) and urine rose 4- to 38-fold (P < 0.01). The decreases in CL am and the GFR markers (CL cr , CL sini ) were proportional, reflecting the extent to which endotoxemia impaired the major elimination mechanism for the drug. Terlipressin attenuated lipopolysaccharide-induced renal dysfunction (urine output, CL cr , CL sini ) and accelerated CL am . The pNGAL showed a strong association with the CL sini (rs = - 0.77, P < 0.0005). Concerning prediction of CL am , pNGAL was comparable to CL cr (mean error - 24%) and inferior to CL sini (mean error - 6.4%), while the measurement of NGAL in urine gave unsatisfactory results.
      Conclusions: During early endotoxemia in the rat, pNGAL has a moderate predictive ability towards CL am . Clinical studies should verify whether pNGAL can support individualized dosing of aminoglycosides to septic patients.
    • References:
      Crit Care Med. 2017 Aug;45(8):e821-e830. (PMID: 28430696)
      Acta Physiol (Oxf). 2017 Mar;219(3):554-572. (PMID: 27474473)
      Biometals. 2006 Apr;19(2):211-5. (PMID: 16718606)
      Int Urol Nephrol. 2018 Apr;50(4):705-713. (PMID: 29307055)
      Drugs. 2011 Dec 3;71(17):2277-94. (PMID: 22085385)
      Intern Med J. 2011 Jun;41(6):441-9. (PMID: 21309997)
      BMC Nephrol. 2012 Jun 27;13:25. (PMID: 22564340)
      J Clin Pharmacol. 2016 Mar;56(3):307-15. (PMID: 26222202)
      Antimicrob Agents Chemother. 1990 Apr;34(4):576-80. (PMID: 2344164)
      Crit Care. 2009;13(4):R130. (PMID: 19664253)
      Anal Biochem. 2001 Feb 1;289(1):10-7. (PMID: 11161289)
      J Surg Res. 2014 May 15;188(2):503-9. (PMID: 24582066)
      J Clin Invest. 2005 Mar;115(3):610-21. (PMID: 15711640)
      J Leukoc Biol. 2007 Jan;81(1):137-43. (PMID: 17020929)
      Crit Care Med. 2009 Mar;37(3):840-51; quiz 859. (PMID: 19237886)
      Ann Lab Med. 2017 Sep;37(5):388-397. (PMID: 28643487)
      Naunyn Schmiedebergs Arch Pharmacol. 2006 Jun;373(3):204-11. (PMID: 16736157)
      Biomarkers. 2013 Jun;18(4):349-56. (PMID: 23627612)
      Scand J Clin Lab Invest. 1995 Nov;55(7):577-88. (PMID: 8633182)
      J Antimicrob Chemother. 2017 Jan;72(1):254-260. (PMID: 27585963)
      Int J Antimicrob Agents. 2010 Dec;36(6):545-8. (PMID: 20863668)
      PLoS One. 2015 Apr 20;10(4):e0124429. (PMID: 25893429)
      Adv Chronic Kidney Dis. 2018 Jan;25(1):84-92. (PMID: 29499892)
      Kidney Int. 2007 May;71(10):967-70. (PMID: 17342180)
      Am J Physiol Renal Physiol. 2015 Mar 1;308(5):F388-99. (PMID: 25503728)
      Drug Metab Pharmacokinet. 2004 Jun;19(3):159-70. (PMID: 15499183)
      Crit Care. 2013 Mar 19;17(2):419. (PMID: 23514603)
      Clin Pharmacokinet. 2017 Feb;56(2):127-138. (PMID: 27324191)
    • Grant Information:
      Progres Q40 Grantová Agentura České Republiky
    • Accession Number:
      0 (Biomarkers)
      0 (Cytokines)
      0 (Lipocalin-2)
      0 (Lipopolysaccharides)
      0 (Oligosaccharides)
      84319SGC3C (Amikacin)
      Y83V3FE29B (sinistrin)
    • Publication Date:
      Date Created: 20191013 Date Completed: 20200924 Latest Revision: 20200924
    • Publication Date:
      20240105
    • Accession Number:
      10.1007/s13318-019-00579-3
    • Accession Number:
      31605364